

	INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No.: 18184-0004-00-US	Serial No.: 10/728,261
	PTO Form 1449	Applicants Herbert W. HARRIS <i>et al.</i>	Page 1 of 1
		Filing Date: December 3, 2003	Group Art Unit: 1617

### U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	RE 30,014	05-29-1979	Korosi <i>et al.</i>			
	4,025,528	05-1977	Maeda <i>et al.</i>			
	5,457,118	10-1995	Dickinson <i>et al.</i>			
	6,291,530	09-2001	Greenspan <i>et al.</i>			
	6,683,072	01-27-2004	Kucharik <i>et al.</i>			
	2004/0138209	07-15-2004	Kucharik <i>et al.</i>			
	2004/0138210	07-15-2004	Harris <i>et al.</i>			
	2004/0157833	08-12-2004	Harris <i>et al.</i>			
	2004/0162284	08-19-2004	Harris <i>et al.</i>			
	2004/0224943	11-11-2004	Leventer <i>et al.</i>			
	2004/0229866	11-18-2004	Harris <i>et al.</i>			
	2004/0254173	12-16-2004	Leventer <i>et al.</i>			
	2005/0075329	04-07-2005	Leventer <i>et al.</i>			
	2005/0288277	12-29-2005	Kucharik <i>et al.</i>			
	2007/0032479	02-08-2007	Leventer <i>et al.</i>			

### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation	
						YES	NO
	02/094189	11-28-2002	WO				
	00/24400	05-04-2000	WO				
	492 485	07-01-1992	EP			Abstract	
	92/11262	07-09-1992	WO			Abstract	
	178519	03-31-1983	HU			X	

### OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No.: 18184-0004-00-US		Serial No.: 10/728,261	
				Applicants Herbert W. HARRIS <i>et al.</i>		Page 1 of 1	
<b>PTO Form 1449</b>				Filing Date: December 3, 2003		Group Art Unit: 1617	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	<u>Translation</u> YES NO
<b>OTHER DOCUMENTS</b>							
(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)							
		CA97:6331(Toke), 1982.					
		Y. ADACHI <i>et al.</i> , "Use of tofisopam (Grandaxin®) in autonomic imbalance and irritable bowel syndrome", <i>Igaku to Yakugaku</i> , 1987, 18(5), 1591-94, Japan. (Translation provided.)					
		T. AOYAGI <i>et al.</i> , Yakuri to Chiryo, "Clinical evaluation of tofisopam (grandaxin®) in various unidentified gastrointestinal complaints", 1992, 20(2), 295-305, Japan. (Translation provided.)					
		S. ASANO <i>et al.</i> , "Study of the efficacy and safety of grandaxin tablets in vague complaints associated with gastrointestinal conditions", <i>Shinyaku to Rinsho</i> , 1993, 42(12), 95-100, Japan. (Translation provided.)					
		V.S. CHADWICK, <i>et al.</i> , "Activation of the mucosal immune system in irritable bowel syndrome", <i>Gastroenterology</i> , 2002, 122(7), 1778-83.					
		S.M. COLLINS, <i>et al.</i> , "The putative role of inflammation in the irritable bowel syndrome", <i>Gut</i> , 2001, 49(6), 743-45.					
		M. CSILLAG <i>et al.</i> , "The treatment of climacteric syndrome with tofisopam (grandaxin)", <i>Ther Hung</i> , 1975, 23(4), 164-69.					
		F. GALDIERO, <i>et al.</i> , "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", <i>Life Sciences</i> , Vol. 57. No. 26, pp. 2413-2423, 1995					
		A. KATO <i>et al.</i> , "Clinical report on grandaxin for various unidentified complaints", <i>Yakuri to Chiryo</i> , 1987, 15(8), 163-71, Japan. (Translation provided.)					
		S. KISHIMOTO <i>et al.</i> , "Clinical effect of grandaxin on dyspeptic patients", <i>Yakuri to Chiryo</i> , 1989, 17(5): 457-64, Japan. (Translation provided.)					
		A. KITANO <i>et al.</i> , "Clinical effect of tofisopam (grandaxin®) on vague gastrointestinal complaints", <i>Shinyaku to Rinsho</i> , 1988, 37(9), 169-73, Japan. (Translation provided.)					
		M. KOJIMA, <i>et al.</i> , "Effects of Tofisopam on Lower Digestive Tract Dysfunction", <i>Clinical Report</i> , 1996, 30(5), 989-94. (Translation provided.)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No.: 18184-0004-00-US		Serial No.: 10/728,261	
				Applicants Herbert W. HARRIS <i>et al.</i>		Page 1 of 1	
PTO Form 1449				Filing Date: December 3, 2003		Group Art Unit: 1617	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation YES NO
<b>OTHER DOCUMENTS</b>							
(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)							
		Y. MATSUO, et al., "Effect of Tofisopam on Experimental Ulcers", <i>Yakuri to Chiryō</i> , 1998, 16(8), 157-64. (Translation provided.)					
		M. OSIPIENKO <i>et al.</i> , "Role of grandaxin in the treatment of functional diseases of the gastrointestinal tract.", <i>Terapevt. Arkhiv</i> , 2000, 10, 23-27. (Translation provided.)					
		O. OYESANMI, <i>et al.</i> , "Hematologic Side Effects of Psychotropics", <i>Psychosomatics</i> , 1999, 40(5), 414-21.					
		J. RISTELHUEBER <i>et al.</i> , "Utility of a new anxiolytic, tofisopam, in current gastroenterology practice," <i>Revue Francaise de Gastro-Enterologie</i> , 1977, 125, 49-52, France. (Translation provided.)					
		J. SZEGŐ <i>et al.</i> , "Selected passages from the clinical-pharmacological and clinical trials of grandaxin", <i>Acta Pharm. Hung.</i> , 1993, 63, 91-98, Hungary. (Translation provided.)					
		H. TAKADA <i>et al.</i> , "Clinical study of grandaxin for unidentified complaints", <i>Yakuri to Chiryō</i> , 1989, 17(3), 381-92, Japan. (Translation provided.)					
		K. YOSHIKAWA <i>et al.</i> , "Clinical evaluation of grandaxin® (tofisopam) on several skin diseases," <i>Hifu</i> , 1993, 35(1), 195-202, Japan. (Translation provided.)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /K/



# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket No.:

18184-0004-00-US

Applicants

Herbert W. HARRIS *et al.*

Filing Date:

December 3, 2003

Serial No.:

10/728,261

Page 1 of 1

Group Art Unit:

1617

## U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date
	RE 30,014	05-29-1979	Korosi <i>et al.</i>			
	4,025,528	05-1977	Maeda <i>et al.</i>			
	5,457,118	10-1995	Dickinson <i>et al.</i>			
	6,291,530	09-2001	Greenspan <i>et al.</i>			
	6,683,072	01-27-2004	Kucharik <i>et al.</i>			
	2004/0138209	07-15-2004	Kucharik <i>et al.</i>			
	2004/0138210	07-15-2004	Harris <i>et al.</i>			
	2004/0157833	08-12-2004	Harris <i>et al.</i>			
	2004/0162284	08-19-2004	Harris <i>et al.</i>			
	2004/0224943	11-11-2004	Leventer <i>et al.</i>			
	2004/0229866	11-18-2004	Harris <i>et al.</i>			
	2004/0254173	12-16-2004	Leventer <i>et al.</i>			
	2005/0075329	04-07-2005	Leventer <i>et al.</i>			
	2005/0288277	12-29-2005	Kucharik <i>et al.</i>			
	2007/0032479	02-08-2007	Leventer <i>et al.</i>			

## FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation YES	NO
02/094189	11-28-2002	WO				
00/24400	05-04-2000	WO				
492 485	07-09-1992	EP			Abstract	
92/11262	07-09-1992	WO			Abstract	
178519	03-31-1983	HU			X	

## OTHER DOCUMENTS

(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No.: 18184-0004-00-US		Serial No.: 10/728,261	
				Applicants Herbert W. HARRIS <i>et al.</i>		Page 1 of 1	
<b>PTO Form 1449</b>				Filing Date: December 3, 2003		Group Art Unit: 1617	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation YES NO
<b>OTHER DOCUMENTS</b>							
(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)							
		CA97:6331(Toke), 1982.					
		Y. ADACHI <i>et al.</i> , "Use of tofisopam (Grandaxin®) in autonomic imbalance and irritable bowel syndrome", <i>Igaku to Yakugaku</i> , 1987, 18(5), 1591-94, Japan. (Translation provided.)					
		T. AOYAGI <i>et al.</i> , Yakuri to Chiryō, "Clinical evaluation of tofisopam (grandaxin®) in various unidentified gastrointestinal complaints", 1992, 20(2), 295-305, Japan. (Translation provided.)					
		S. ASANO <i>et al.</i> , "Study of the efficacy and safety of grandaxin tablets in vague complaints associated with gastrointestinal conditions", <i>Shinyaku to Rinsho</i> , 1993, 42(12), 95-100, Japan. (Translation provided.)					
		V.S. CHADWICK, <i>et al.</i> , "Activation of the mucosal immune system in irritable bowel syndrome", <i>Gastroenterology</i> , 2002, 122(7), 1778-83.					
		S.M. COLLINS, <i>et al.</i> , "The putative role of inflammation in the irritable bowel syndrome", <i>Gut</i> , 2001, 49(6), 743-45.					
		M. CSILLAG <i>et al.</i> , "The treatment of climacteric syndrome with tofisopam (grandaxin)", <i>Ther Hung</i> , 1975, 23(4), 164-69.					
		F. GALDIERO, <i>et al.</i> , "Effects of Benzodiazepines on Immunodeficiency and Resistance in Mice", <i>Life Sciences</i> , Vol. 57. No. 26, pp. 2413-2423, 1995					
		A. KATO <i>et al.</i> , "Clinical report on grandaxin for various unidentified complaints", <i>Yakuri to Chiryō</i> , 1987, 15(8), 163-71, Japan. (Translation provided.)					
		S. KISHIMOTO <i>et al.</i> , "Clinical effect of grandaxin on dyspeptic patients", <i>Yakuri to Chiryō</i> , 1989, 17(5): 457-64, Japan. (Translation provided.)					
		A. KITANO <i>et al.</i> , "Clinical effect of tofisopam (grandaxin®) on vague gastrointestinal complaints", <i>Shinyaku to Rinsho</i> , 1988, 37(9), 169-73, Japan. (Translation provided.)					
		M. KOJIMA, <i>et al.</i> , "Effects of Tofisopam on Lower Digestive Tract Dysfunction", <i>Clinical Report</i> , 1996, 30(5), 989-94. (Translation provided.)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/



<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No.: 18184-0004-00-US		Serial No.: 10/728,261	
				Applicants Herbert W. HARRIS <i>et al.</i>		Page 1 of 1	
PTO Form 1449				Filing Date: December 3, 2003		Group Art Unit: 1617	
<b>U.S. PATENT DOCUMENTS</b>							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Class	Sub Class	Translation YES NO
<b>OTHER DOCUMENTS</b>							
(Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s).)							
		Y. MATSUO, <i>et al.</i> , "Effect of Tofisopam on Experimental Ulcers", <i>Yakuri to Chiryo</i> , 1998, 16(8), 157-64. (Translation provided.)					
		M. OSIPENKO <i>et al.</i> , "Role of grandaxin in the treatment of functional diseases of the gastrointestinal tract.", <i>Terapevt. Arkhiv</i> , 2000, 10, 23-27. (Translation provided.)					
		O. OYESANMI, <i>et al.</i> , "Hematologic Side Effects of Psychotropics", <i>Psychosomatics</i> , 199, 40(5), 414-21.					
		J. RISTELHUEBER <i>et al.</i> , "Utility of a new anxiolytic, tofisopam, in current gastroenterology practice," <i>Revue Francaise de Gastro-Enterologie</i> , 1977, 125, 49-52, France. (Translation provided.)					
		J. SZEGÓ <i>et al.</i> , "Selected passages from the clinical-pharmacological and clinical trials of grandaxin", <i>Acta Pharm. Hung.</i> , 1993, 63, 91-98, Hungary. (Translation provided.)					
		H. TAKADA <i>et al.</i> , "Clinical study of grandaxin for unidentified complaints", <i>Yakuri to Chiryo</i> , 1989, 17(3), 381-92, Japan. (Translation provided.)					
		K. YOSHIKAWA <i>et al.</i> , "Clinical evaluation of grandaxin® (tofisopam) on several skin diseases," <i>Hifu</i> , 1993, 35(1), 195-202, Japan. (Translation provided.)					
Examiner	/Kendra Carter/				Date Considered 04/23/2008		
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KC/